Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies

Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a leading blood-stage malaria vaccine antigen target, currently in a phase 2b clinical trial as a full-length soluble protein/adjuvant vaccine candidate called RH5.1/Matrix-M. We identify that disordered regions of the full-length...

Cijeli opis

Bibliografski detalji
Glavni autori:	King, LDW, Pulido, D, Barrett, JR, Davies, H, Quinkert, D, Lias, AM, Silk, SE, Pattinson, DJ, Diouf, A, Williams, BG, McHugh, K, Rodrigues, A, Rigby, CA, Strazza, V, Suurbaar, J, Rees-Spear, C, Dabbs, RA, Ishizuka, AS, Zhou, Y, Gupta, G, Jin, J, Li, Y, Carnrot, C, Minassian, AM, Campeotto, I, Fleishman, SJ, Noe, AR, MacGill, RS, King, CR, Birkett, AJ, Soisson, LA, Long, CA, Miura, K, Ashfield, R, Skinner, K, Howarth, MR, Biswas, S, Draper, SJ
Format:	Journal article
Jezik:	English
Izdano:	Cell Press 2024

Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies

Slični predmeti